Autism Waiver services enable individuals who have Autism Spectrum Disorder and who meet an institutional level of care to be supported in their own homes or community-based settings. This infographic provides information about Maryland Medicaid participants who received services through the Autism Waiver in fiscal years (FYs) 2016 through 2020.
The objectives of this research are to determine a potential policy alternative to the current recommended budgeting methodology and to simulate the gains in administrative efficiency on actual Maryland Medicaid data from FY 2019. The broader hope is that this study can potentially serve as a guide to other states that are considering adoption of the Community First Choice program.
Senior Director of Research and Analytics/Chief Data Scientist Ian Stockwell, PhD, and Principal Data Scientist Morgan Henderson, PhD, co-authored this article published in the American Journal of Managed Care.
This chart book, prepared for the Maryland Department of Health, compares the FY 2022 Medicaid reimbursement rates of Maryland and its surrounding states with Maryland’s Medicare fee schedule for CY 2021 for the Baltimore region. The surrounding states included in this study are Washington, DC; Delaware; Pennsylvania; Virginia; and West Virginia.
In 1997, Maryland implemented HealthChoice—a statewide mandatory Medicaid and Children’s Health Insurance Program (CHIP) managed care program—under authority of a waiver through §1115 of the Social Security Act. The provisions of the Affordable Care Act (ACA) that went into effect in 2014 marked another milestone by extending quality coverage to many more Marylanders with low income by calendar year (CY) 2018. Over 20 years after its launch, HealthChoice covered close to 90 percent of the state’s Medicaid and Maryland Children’s Health Program (MCHP) populations.
The Hilltop Institute, on behalf of the Maryland Department of Health (the Department), evaluates the program annually; this evaluation covers the period from CY 2016 through CY 2020.
Principal Data Scientist Morgan Henderson, PhD, presented his research in this poster at the 2022 AcademyHealth Annual Research Meeting (ARM) held June 4-7, 2022, in Washington DC. In addition, he served as an expert on a panel that discussed working in the field of health services research.
Data Scientist Leigh Goetschius, PhD, presented her research in this poster at the 2022 AcademyHealth Annual Research Meeting (ARM) held June 4-7, 2022, in Washington DC.
Medication for opioid use disorder (MOUD) reduces harms associated with opioid use disorder (OUD), including risk of overdose. Understanding how variation in MOUD duration influences overdose risk is important as health-care payers increasingly remove barriers to treatment continuation (e.g. prior authorization). This study measured the association between MOUD continuation, relative to discontinuation, and opioid-related overdose among Medicaid beneficiaries.
Senior Policy Analyst Shamis Mohamoud was part of the Medicaid Outcomes Distributed Research Network (MODRN) team of authors of this article published in Addiction.
The Maryland Medicaid Dental Program Chart Book outlines the demographics and service utilization for individuals enrolled in the Maryland Medicaid Dental Program. This chart book provides information about program participants who received services in calendar year (CY) 2016 through CY 2020.
The Maryland Medicaid Dental Program Chart Book outlines the demographics and service utilization for individuals enrolled in the Maryland Medicaid Dental Program. This chart book provides information about program participants who received services in calendar year (CY) 2015 through CY 2019.
Follow-up visits within 7 days of an emergency department (ED) visit related to opioid use disorder (OUD) is a key measure of treatment quality, but we know little about its protective effect on future opioid-related overdoses. The objective of this article is to examine the rate of 7-day follow-up after an OUD-related ED visit and the association with future overdoses.
Senior Policy Analyst Shamis Mohamoud was part of the Medicaid Outcomes Distributed Research Network (MODRN) team of authors of this article published in the Journal of Substance Abuse Treatment.
